(Q30361227)

20 June 2017

title

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review. (English)

1 reference

20 June 2017

0 references

1 reference

Martin Rao

3

0 references

Christoph Lange

Christoph Lange

2

0 references

Markus Maeurer

Markus Maeurer

8

0 references

Alimuddin Zumla

Alimuddin I Zumla

7

0 references

Stefan Kaufmann

Stefan H E Kaufmann

1

0 references

Michael T Lotze

5

Michael Lotze

1 reference

20 June 2017

author name string

Kithiganahalli N Balaji

4

1 reference

20 June 2017

Marco Schito

6

1 reference

20 June 2017

publication date

24 March 2014

1 reference

The Lancet. Respiratory medicine

20 June 2017

published in

1 reference

20 June 2017

volume

2

1 reference

20 June 2017

issue

4

1 reference

20 June 2017

page(s)

301-320

1 reference

Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Vaccine design for CD8 T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

T cell-mediated host immune defenses in the lung

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

1 reference

7 January 2021

The many faces of host responses to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Cell-mediated immune responses in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

New insights into the function of granulomas in human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

An antimicrobial activity of cytolytic T cells mediated by granulysin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Recognition of lipid antigens by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Human mucosal associated invariant T cells detect bacterially infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis: success through dormancy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Future Vaccination Strategies against Tuberculosis: Thinking outside the Box

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

New vaccines for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Tuberculosis vaccines: time to think about the next generation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Is adipose tissue a place for Mycobacterium tuberculosis persistence?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis invades and replicates within type II alveolar cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Host-directed therapeutics for tuberculosis: can we harness the host?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A novel human IgA monoclonal antibody protects against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Common polymorphisms in the PKP3-SIGIRR-TMEM16J gene region are associated with susceptibility to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Circulating microRNAs in patients with active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Apoptosis-inducing activity of clofazimine in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence].

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The importance of vitamins D and K for the bone health and immune function in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Vitamin D induces interleukin-1β expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Interleukin-12 as successful adjuvant in tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Valproic acid attenuates lipopolysaccharide-induced acute lung injury in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Immunomodulatory effects of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Reactivation of latent HIV by histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Inhibition of Ca2+-activated K+ current by clotrimazole in rat anterior pituitary GH3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Clotrimazole inhibits cell proliferation in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

When to start antiretroviral therapy during tuberculosis treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autophagy in human health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Association of IRGM polymorphisms and susceptibility to pulmonary tuberculosis in Zahedan, Southeast Iran

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Polymorphic allele of human IRGM1 is associated with susceptibility to tuberculosis in African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autophagy gene variant IRGM -261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Human IRGM induces autophagy to eliminate intracellular mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: diagnostic value and relationship to disease severity and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

In vivo requirement for Atg5 in antigen presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autophagy modulation as a potential therapeutic target for diverse diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autophagy in immunity and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Autophagy, Immunity, and Microbial Adaptations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Development by self-digestion: molecular mechanisms and biological functions of autophagy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Selective inhibition of IFNG-induced autophagy by Mir155- and Mir31-responsive WNT5A and SHH signaling

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Comparative miRNA expression profiles in individuals with latent and active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Regulation of progenitor cell proliferation and granulocyte function by microRNA-223

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Cyclic AMP: master regulator of innate immune cell function.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Requirement for Abl kinases in T cell receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

STAT3, p38 MAPK, and NF-kappaB drive unopposed monocyte-dependent fibroblast MMP-1 secretion in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

SOCS3 promotes interleukin-17 expression of human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Critical and independent role for SOCS3 in either myeloid or T cells in resistance to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The expanding scope of antimicrobial peptide structures and their modes of action

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The role of the multifunctional peptide LL-37 in host defense

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

CD40 ligand and interferon-γ induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Identification of an anti-mycobacterial domain in NK-lysin and granulysin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Granulysin-expressing CD4+ T cells as candidate immune marker for tuberculosis during childhood and adolescence

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Neutrophil-mediated innate immune resistance to mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

1 reference

7 January 2021

Immunological biomarkers of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Tim3 binding to galectin-9 stimulates antimicrobial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Metabolism of inflammation limited by AMPK and pseudo-starvation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Interleukin-2 and regulatory T cells in graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Regulation of immunological homeostasis in the respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Bacterial expression and antibiotic activities of recombinant variants of human β-defensins on pathogenic bacteria and M. tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Vaccines against tuberculosis: where are we and where do we need to go?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

RUTI: a new chance to shorten the treatment of latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium vaccae immunotherapy for treating tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Recombinant live vaccine candidates against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The family of thiol-activated, cholesterol-binding cytolysins

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The second Geneva Consensus: Recommendations for novel live TB vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A small RNA encoded in the Rv2660c locus of Mycobacterium tuberculosis is induced during starvation and infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Taking a New Shot At a TB Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2814%2970033-5

7 January 2021

10.1016/S2213-2600(14)70033-5

Identifiers

DOI

1 reference

20 June 2017

1 reference